Change of SMAD4 after TGFβ inhibitor /activator treatment. by Jingping Ge (636557)

“…Protein levels were measured by Western blot analysis. A) Decrease of total p-SMAD2 after SB431542 treatment in all iPSCs, and increase of p-SMAD2 in both DBA iPSCs after the TGFβ1 treatment. …”

D257A mice display decreased mRNA expression of nuclear genes encoding components of ETC Complexes I, III and IV. by Asimina Hiona (246175)

<i>Zfp92</i> KO mice have increased blood glucose and decreased <i>Mafb</i> and insulin expression at P1. by Anna B. Osipovich (8742198)

Tunable Actuation of Humidity-Driven Artificial Muscles via Graphene Nanofillers by Sevketcan Sarikaya (10317493)

Subjects:

Tunable Actuation of Humidity-Driven Artificial Muscles via Graphene Nanofillers by Sevketcan Sarikaya (10317493)

Subjects:

Decreased remyelination initiation is observed in Scribble cKO mice following focal demyelination in corpus callosum. by Andrew A. Jarjour (343100)

“…In the contralateral (unlesioned) hemisphere (CL), no difference was seen in the proportion of axons in the corpus callosum that were myelinated in Scribble cKO compared to wild-type animals (A–C). Fewer remyelinated axons were observed in corpus callosum in the lesion area in Scribble cKO mice (E) relative to controls (D) as quantified in F; 0.4–0.5 μm: WT = 80.0% ± 9.8%, cKO = 41.3% ± 8.9% myelinated; 0.5–0.6 μm: WT = 79.4% ± 6.3%, cKO = 41.5% ± 9.5% myelinated; 0.6–0.7 μm: WT = 91.6% ± 3.0%, cKO = 44.3% ± 8.7% myelinated; >0.7 μm: WT = 92.7% ± 1.9%, cKO = 47.9% ± 2.5% myelinated. …”

Table1_PagSOD2a improves poplar salt tolerance by elevating superoxide dismutase activity and decreasing malondialdehyde contents.docx by Lieding Zhou (16427928)

Presentation1_PagSOD2a improves poplar salt tolerance by elevating superoxide dismutase activity and decreasing malondialdehyde contents.zip by Lieding Zhou (16427928)

Absence of PICALM results in a decreased rate of internalization and increased cell surface expression of TfR in MEFs. by Paula B. Scotland (138601)

Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

Subjects:

iOWH032 inhibits cholera toxin-induced secretion in a mouse closed-loop model. by Rahsan Erdem (11726357)

Subjects:

Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

Subjects:

Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 1. by Rahsan Erdem (11726357)

Subjects:

Diarrheal stool output rate overall and by blood type status in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Source data for S1 and S2 Figs. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 2. by Rahsan Erdem (11726357)

Subjects:

Consolidated Standards for Reporting of Trials flow diagram. by Rahsan Erdem (11726357)

Subjects:

iOWH032 inhibits cholera toxin-induced fecal output in a cecectomized rat model. by Rahsan Erdem (11726357)

Subjects: